Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PD 0332334 · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| PD 0332334 300 mg BID | EXPERIMENTAL | - |
| Placebo BID | PLACEBO_COMPARATOR | - |
| PD 0332334 225 mg BID | EXPERIMENTAL | - |
| PD 0332334 175 mg BID | EXPERIMENTAL | - |
| PD 0332334 250 mg | EXPERIMENTAL | - |
| PD 0332334 100 mg | EXPERIMENTAL | - |
| placebo | PLACEBO_COMPARATOR | - |
| Alprazolam extended release | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PD 0332334 | DRUG | Capsules, oral, 300 mg BID, 8 weeks with 2 week taper. |
| Placebo | DRUG | Capsules, oral, placebo BID, 8 weeks with 2 week taper. |
| Alprazolam extended release | DRUG | 1 mg capsule, BID for 4 weeks |
Inclusion Criteria: * Diagnosis of GAD (Diagnostic and Statistical Manual-IV \[DSM-IV\], 300.02) as established by the clinician (psychiatrist or licensed clinical psychologist) who has interviewed the subject using all sources of data including the Mini International Neuropsychiatric Interview (MI...
PD 0332334 is an investigational small molecule being developed for Generalized Anxiety Disorder and studied in patients receiving renal dialysis. It has been evaluated in Phase 1, Phase 2, and Phase 3 clinical trials, all of which are completed. The drug is not approved and remains in clinical development.
PD 0332334 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The company has sponsored multiple clinical trials of the drug, including a Phase 3 study in Generalized Anxiety Disorder.
PD 0332334 has completed Phase 3 clinical development. A 10-week Phase 3 study evaluated its efficacy and safety in Generalized Anxiety Disorder, and a Phase 2 trial compared it with alprazolam extended release and placebo. The drug is investigational and not FDA approved.
PD 0332334 has completed three clinical trials: NCT00537615, a Phase 1 absorption, metabolism, and excretion study in healthy volunteers; NCT00542685, a Phase 3 efficacy and safety study in Generalized Anxiety Disorder; and NCT00730145, a Phase 1 study in hemodialysis patients. All trials are completed.
PD 0332334 and PD-0332334 refer to the same investigational drug. Clinical trial records use both spellings, with NCT00730145 titled 'PD-0332334' and other studies using 'PD 0332334'. Both names identify the same Pfizer compound.